PLC’s continued Regulatory support of Intravail® and its technology has assisted in the advancement of ARS-1 and its product development. Neurelis Announces That Intravail® Licensee, ARS Pharmaceuticals’ Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure to Epinephrine Injectors  / 4 May 2020 / 0 Comments — ARS Pharmaceuticals’ lead product, ARS-1 (epinephrine nasal spray) to treat severe allergic reactions, has

PLC’s continued support of Neurelis in regulatory filings and clinical trial development, site management, data management for multiple successful trials and new product development results in approval and commercial availability of Valtoco®. Neurelis Announces Commercial Availability- Valtoco® (Diazepam Nasal Spray) for Seizure Cluster Rescue — VALTOCO is the first and only nasal spray treatment for